Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231894 · ClinicalTrials.gov registry record · Phase 4
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
A Phase 4 study, sponsored by Nathan Kline Institute for Psychiatric Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT00231894: Completed Phase 4 study, sponsored by Nathan Kline Institute for Psychiatric Research.
NCT00231894 is a Phase 4 study that has completed, run by Nathan Kline Institute for Psychiatric Research. The registered enrollment target is 56 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00231894, a Phase 4 study, has completed, sponsored by Nathan Kline Institute for Psychiatric Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics, and comparison of effects of this drug with another treatment lifestyle modification. Patients who meet inclusion criteria will be treated with pioglitazone for 12 weeks. They will be evaluated for fasting glucose and lipids, glucose-tolerance tests, and neurocognitive battery and tests of verbal memory at baseline and during treatment with pioglitazone.
Interventions
- OTHER Placebo
- DRUG Pioglitazone
- BEHAVIORAL Life style diet group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2005-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
What the finished NCT00231894 record still lists
NCT00231894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00231894 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00231894 about?
NCT00231894 is a clinical study titled "Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia". This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics, and comparison of effects of this drug with another treatment lifestyle modification. Patients who...
What is the current status of trial NCT00231894?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2005-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00231894?
The interventions under investigation include: Placebo (OTHER), Pioglitazone (DRUG), Life style diet group (BEHAVIORAL).
Who is sponsoring clinical trial NCT00231894?
This trial is sponsored by Nathan Kline Institute for Psychiatric Research, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00231894's enrollment target sits among peer trials
56 1213th of 2000 higher than 783 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia